Next Article in Journal
Diphlorethohydroxycarmalol Attenuates Palmitate-Induced Hepatic Lipogenesis and Inflammation
Next Article in Special Issue
On a Beam of Light: Photoprotective Activities of the Marine Carotenoids Astaxanthin and Fucoxanthin in Suppression of Inflammation and Cancer
Previous Article in Journal
Jeju Magma-Seawater Inhibits α-MSH-Induced Melanogenesis via CaMKKβ-AMPK Signaling Pathways in B16F10 Melanoma Cells
Previous Article in Special Issue
Oxidative Stress and Marine Carotenoids: Application by Using Nanoformulations
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 18
Issue 9
10.3390/md18090474
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antitumour Effects of Astaxanthin and Adonixanthin on Glioblastoma

by
Shohei Tsuji
1,
Shinsuke Nakamura
1,*,
Takashi Maoka
2,
Tetsuya Yamada
1,3,
Takahiko Imai
1,
Takuya Ohba
1,
Tomohiro Yako
1,
Masahiro Hayashi
4,
Ken Endo
5,
Masanao Saio
6,
Hideaki Hara
1 and
Masamitsu Shimazawa
1
1
Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, Gifu 501-1196, Japan
2
Research Institute for Production Developent Division of Food Function and Chemistry, Kyoto 606-0805, Japan
3
Department of Neurosurgery, Gifu University School of Medicine, Gifu 501-1194, Japan
4
Department of HPM Research & Development, Biotechnology R&D Group, High Performance Materials Company, ENEOS Corporation, Yokohama 231-0815, Japan
5
Department of HPM Business Promotion Group V, Business promotion Group, High Performance Materials Company, ENEOS Corporation, Tokyo 108-8005, Japan
6
Graduate School of Health Sciences, Gunma University, Gunma 371-8514, Japan
*
Author to whom correspondence should be addressed.
Mar. Drugs 2020, 18(9), 474; https://doi.org/10.3390/md18090474
Submission received: 22 July 2020 / Revised: 16 September 2020 / Accepted: 16 September 2020 / Published: 18 September 2020
(This article belongs to the Special Issue Marine Carotenoids in Inflammation and Cancer)
Browse Figures
Review Reports Versions Notes

Abstract

:
Several antitumour drugs have been isolated from natural products and many clinical trials are underway to evaluate their potential. There have been numerous reports about the antitumour effects of astaxanthin against several tumours but no studies into its effects against glioblastoma. Astaxanthin is a red pigment found in crustaceans and fish and is also synthesized in Haematococcus pluvialis; adonixanthin is an intermediate product of astaxanthin. It is known that both astaxanthin and adonixanthin possess radical scavenging activity and can confer a protective effect on several damages. In this study, we clarified the antitumour effects of astaxanthin and adonixanthin using glioblastoma models. Specifically, astaxanthin and adonixanthin showed an ability to suppress cell proliferation and migration in three types of glioblastoma cells. Furthermore, these compounds were confirmed to transfer to the brain in a murine model. In the murine orthotopic glioblastoma model, glioblastoma progression was suppressed by the oral administration of astaxanthin and adonixanthin at 10 and 30 mg/kg, respectively, for 10 days. These results suggest that both astaxanthin and adonixanthin have potential as treatments for glioblastoma.

1. Introduction

Glioblastoma is one of the most lethal types of brain tumour; it arises from glial cells [1,2]. The standard treatment for glioblastoma is a combination of chemotherapy and radiotherapy following the surgical removal of tumour tissue [3]. However, glioblastomas generally show a poor prognosis and short survival time, rarely longer than 14 months [4]. The poor prognosis is attributed to chemoresistance to temozolomide, the first-line drug for the treatment of glioblastoma [5]. Therefore, it is essential that novel drugs are developed that possess an antitumour effect based on different mechanisms to those of temozolomide. However, the development of novel drugs for glioblastoma has been limited by the blood–brain barrier (BBB) issue [6]. Recent studies have shown that certain compounds derived from natural products, such as curcumin and resveratrol, can cross the BBB and have an antitumour effect against glioblastoma [7,8]. Both powerful antitumour effects and transferability to brain tissues are essential requirements for any new treatments for glioblastoma.
In this study, we focused on a xanthophyll carotenoid, astaxanthin, and its intermediate product, adonixanthin (Figure 1) [9]. Astaxanthin, a red pigment that occurs naturally in shrimp, crab, and salmon [10], is a powerful antioxidant and has shown some protective effects in various oxidative stress and disease models [11,12,13,14,15]. Adonixanthin has similarly powerful antioxidative effects [9,16]. Crucially, it has been reported that, in mouse models, both astaxanthin and adonixanthin have the ability to cross the BBB to reach the brain tissue and can protect vessels in the brain from cerebral ischaemia and haemorrhage [17,18]. However, there have been no reports that either astaxanthin or adonixanthin have antitumour effects against glioblastoma. It is known that astaxanthin has antitumour effects against oral cancer, bladder carcinogenesis, colon carcinogenesis, leukaemia, and hepatocellular carcinoma [19,20,21,22,23]; however, the mechanisms for this antitumour activity of astaxanthin are yet to be fully clarified. It has been reported that the antitumour effect of astaxanthin and adonixanthin are mediated by multiple mechanisms, including JAK-2/STAT-3, NF-κB, ERK, AKT (PKB), PPARγ, and Nrf2 [24].
The purpose of this study was to clarify whether astaxanthin and adonixanthin have antitumour effects against glioblastoma following their oral administration. Furthermore, we aimed to verify whether orally administered astaxanthin or adonixanthin can be absorbed by the brain tissue. We investigated the antitumour mechanisms of astaxanthin and adonixanthin using glioblastoma cells.

2. Results

2.1. Astaxanthin and Adonixanthin Suppressed the Growth of Glioblastoma Cells

Robust cell viability is an important characteristic of tumour cells. We performed a cell viability assay using the murine glioblastoma cell line GL261 and the human glioblastoma cell line U251MG. Both astaxanthin and adonixanthin showed antitumour effects against GL261 and U251MG cells, in a concentration-dependent manner (Figure 2A,B). In GL261 cells, astaxanthin and adonixanthin suppressed cell viability at concentrations of more than 5 and 0.1 µM (Figure 2A). In U251MG cells, astaxanthin and adonixanthin suppressed cell viability at concentrations of more than 1 and 0.1 µM (Figure 2B). Moreover, we performed the BrdU cell proliferation assay to determine whether the results of cell viability by astaxanthin and adonixanthin (Figure 2A,B) are based on proliferation. Astaxanthin and adonixanthin at the 10 µM treatment for 72 h reduced the number of BrdU-positive cells (Figure 2C,D). The BrdU-positive cell rates were 60.56 ± 1.40% (control group), 19.17 ± 1.77% (temozolomide group), 49.13 ± 2.66% (astaxanthin group), and 41.31 ± 1.51% (adonixanthin group).

2.2. Astaxanthin and Adonixanthin Suppressed the Migration of Glioblastoma Cells

In addition to cell viability, cell migration is also important for tumour enlargement. We performed a wound healing assay using the murine glioblastoma cell line GL261 and the human glioblastoma cell line U251MG. Astaxanthin and adonixanthin suppressed cell migration by 8.84 ± 2.09% and 13.74 ± 4.01% in GL261, respectively (Figure 3A,B). Astaxanthin and adonixanthin suppressed cell migration by 21.15 ± 1.84% and 26.32 ± 5.14% in U251MG, respectively, at a concentration of 10 µM (Figure 3C,D).

2.3. Astaxanthin and Adonixanthin Decreased the Expression of Some Proteins to Promote Cell Growth and Migration

We performed immunoblotting to reveal the mechanisms of the antitumour effects of astaxanthin and adonixanthin. In general, the phosphorylation of ERK1/2 and Akt are accelerated during tumour progression in many types of tumour [25,26]. The phosphorylation of ERK1/2 and Akt were decreased 6 h post-treatment with astaxanthin and adonixanthin (Figure 4A,B). Both astaxanthin and adonixanthin treatment for 48 h increased the phosphorylation of p38 mitogen-activated protein kinase: MAPK (Figure 4C). To elucidate the antitumour effect of astaxanthin and adonixanthin, we confirmed the expression of cyclin D1 (cell cycle-related protein) and p27 (cyclin-dependent kinase inhibitor). As a result, both astaxanthin and adonixanthin treatment for 48 h decreased the expression of cyclinD1 (Figure 4D) and increased the expression of p27 (Figure 4E). Next, we focused on some proteins that are related to cell migration (Matrix metalloproteinase-2, -9: MMP-2, -9, and fibronectin). Treatment with astaxanthin and adonixanthin for 48 h decreased MMP-2 expression (Figure 4F) but not MMP-9 expression (Figure 4G). Interestingly, adonixanthin also decreased the expression of fibronectin (Figure 4H).

2.4. Astaxanthin and Adonixanthin Decreased the Production of Reactive Oxygen Species (ROS)

In previous reports, the presence of ROS was shown to promote tumour progression via the phosphorylation of ERK1/2 and Akt [27,28]. Therefore, we performed an ROS assay to investigate the effects of astaxanthin and adonixanthin on the level of intracellular ROS. Both astaxanthin and adonixanthin decreased the amount of intracellular ROS, with the effect of adonixanthin stronger than that of astaxanthin (Figure 5A). We also verified the expression of NADPH oxidase 4 (Nox4), which is a representative factor to produce ROS. Adonixanthin significantly decreased the expression of Nox4, whereas astaxanthin produced no change in Nox4 expression (Figure 5B).

2.5. Concentrations of Astaxanthin and Adonixanthin in Murine Serum and Tissues

Following the oral administration of astaxanthin, the concentration of trans- or cis-astaxanthin in the serum was 6.04 ± 1.16 and 13.35 ± 3.78 ng/mL, respectively. Astaxanthin was not detected in the serum in pretreatment samples (Table 1). Adonixanthin was also only detected in the treated group. The levels of trans- and cis- adonixanthin were 34.72 ± 3.00 and 35.02 ± 5.01 ng/mL, respectively (Table 1). In the adonixanthin-treated group, the trans-isomer was detected significantly more frequently compared with its detection in the astaxanthin-treated group.
As shown in Table 2, following oral administration of astaxanthin or adonixanthin, these compounds were absorbed in each region of the brain in mice. Trans-astaxanthin was detected at 5.22 ± 0.87, 5.06 ± 1.85, 11.37 ± 3.14, and 12.28 ± 1.07 ng/g in the cerebral cortex, the cerebellum, the striatum, and the hippocampus of astaxanthin-treated mice, respectively. Cis-astaxanthin was detected at 3.62 ± 1.56, 2.43 ± 1.58, 3.76 ± 2.06, and 2.61 ± 2.67 ng/g in the cerebral cortex, the cerebellum, the striatum, and the hippocampus of astaxanthin-treated mice, respectively. Trans-adonixanthin was detected at 3.24 ± 0.44, 2.85 ± 1.05, 2.90 ± 1.87, and 3.63 ± 2.10 ng/g in the cerebral cortex, the cerebellum, the striatum, and the hippocampus of adonixanthin-treated mice, respectively. There was no cis-astaxanthin in any of the brain tissues. Furthermore, neither astaxanthin nor adonixanthin were detected in the brains of the vehicle-treated group.

2.6. The Effects of Astaxanthin and Adonixanthin on Body Weight

To investigate systemic influences following the administration of astaxanthin and adonixanthin, we explored changes in the body weight of mice. The weight of vehicle-, astaxanthin-, and adonixanthin-treated mice at pretreatment was 34.33 ± 2.04, 34.28 ± 1.93, and 34.22 ± 2.67 g, respectively. After 10 days of administration, the weight of vehicle-, astaxanthin-, and adonixanthin-treated mice was 34.72 ± 2.05, 35.50 ± 1.95, and 36.15 ± 2.05 g, respectively (Supplementary Material Figure S5). No significant changes in body weight were observed in mice treated with either astaxanthin or adonixanthin.

2.7. Astaxanthin and Adonixanthin Showed Antitumour Effects in a Murine Orthotopic Glioblastoma Model

We investigated whether astaxanthin and adonixanthin exhibited antitumour effects in a murine orthotopic glioblastoma model. Treatment with astaxanthin and adonixanthin at 10 and 30 mg/kg for 10 days, respectively, significantly suppressed tumour enlargement (Figure 6A,B).

3. Discussion

Astaxanthin and adonixanthin, synthesized in marine organisms [10], have antitumour properties [9] and a therapeutic effect on the central nervous system [18,29]. However, there are no reports about their effects for glioma. In the present study, we demonstrated the antitumour effects of these compounds in both in vitro and in vivo glioblastoma models.
Astaxanthin and adonixanthin inhibited both cell proliferation and migration in human and mouse glioblastoma cells (Figure 2 and Figure 3). Next, in order to elucidate the antitumour mechanism of astaxanthin and adonixanthin, the expression of proteins related to tumour progression and the degree of ROS production were examined using the mouse glioblastoma cell line GL261. Astaxanthin and adonixanthin were found to reduce the expression of phosphorylated ERK1/2 and phosphorylated Akt (Figure 3A,B). It was shown that astaxanthin exhibited an antitumour effect in an oral cancer model via the suppression of phosphorylation of ERK1/2 and Akt [19]. Similarly, it is presumed that astaxanthin and adonixanthin also have an antitumour effect against glioblastoma through the inhibition of the phosphorylation of ERK1/2 and Akt. Furthermore, astaxanthin and adonixanthin increased the expression of phosphorylated p38 (Figure 4C). The phosphorylation of p38 can lead to cell damage and cell cycle arrest [30]. Therefore, the antitumour effects of both astaxanthin and adonixanthin were involved in increasing the expression of phosphorylated p38. To elucidate the antitumour effect of these compounds, we confirmed the expression of cell cycle-related protein cyclin D1, and apoptosis-related protein Bcl-2. These compounds decreased the expression of cyclin D1 (Figure 4D) but not Bcl2 (Supplementary Material Figure S4b). In fact, these compounds did not induce cell death in GL261 (Supplementary Material Figure S4a) and decreased the cell proliferation in GL261 (Figure 2C,D). Moreover, these compounds increased the expression of p27, a cyclin-dependent kinase inhibitor (Figure 4E). In a previous report, the phosphorylation of ERK1/2 and Akt increased the expression of cyclinD1 and decreased the expression of p27 [31,32,33]. These results indicate that the antitumour effect of both astaxanthin and adonixanthin may be mediated by not cell death but cell cycle arrest. Temozolomide significantly reduced the expression of p27 (Figure 4E). This may be due to a feedback to the potent cell cycle arrest effect of temozolomide, as previously reported [34]. Additionally, adonixanthin reduced the expression of MMP-2 and fibronectin, downstream of ERK1/2 and Akt signalling (Figure 4E,G). In addition, both astaxanthin and adonixanthin decreased the mRNA level of fibronectin (Supplementary Material Figure 3). These results indicate that adonixanthin could affect ERK1/2 and Akt signalling upstream. In MMP9, the reason why there were no changes in the expression (Figure 3F) may be that it is an inflammation-related enzyme, the expression of which is low in the normal condition.
To elucidate the active site of both compounds, we examined their effect on ROS, which is important for the regulation of both ERK1/2 and Akt phosphorylation [35]. In the past, it has been reported that ROS promote tumour progression via the phosphorylation of ERK1/2 and Akt [27,30]. Therefore, we evaluated the level of ROS in glioblastoma cells following treatment with both compounds for 6 h. Both compounds greatly reduced the levels of intracellular ROS (Figure 5A). Astaxanthin and adonixanthin have been reported to possess radical scavenging properties [9], and the reduction of reactive oxygen species in glioblastoma cells shown in this study may also include the direct antioxidant activity of these compounds. Nox4 is a key factor involved in the regulation of ROS production and is upregulated in glioblastoma compared with other nicotinamide adenine dinucleotide phosphate: NADPH oxidase isoforms [36]. Only adonixanthin significantly suppressed the expression of Nox4 (Figure 5B). As the effect of adonixanthin on intracellur ROS in glioblastoma cells, it is considered that adonixanthin may inhibit the expression of ROS production-related factors, such as Nox4.
We examined whether astaxanthin and adonixanthin can be delivered to the brain following oral administration, using healthy mice. We confirmed that both compounds were delivered to the brain, that astaxanthin was detected at a higher concentration than adonixanthin in the brain tissue, and that the cis-form of adonixanthin was not detected at all in any brain tissues (Table 2). Conversely, adonixanthin was detected at high levels in mouse tissues other than the brain (Supplementary Material Table S1). It is suggested that orally administered adonixanthin mainly affects the peripheral tissues due to the difference in the distribution of adonixanthin. In this study, we used structurally stable trans-isomers of both astaxanthin and adonixanthin. The trans-form of astaxanthin and adonixanthin is converted to the cis-form in the blood following oral administration [37]. The differences in the structure between the cis- and trans-forms may affect their antitumour activity, and although the cis-form of astaxanthin has been reported to show greater antioxidant activity than the trans-form [38], the detailed mechanism underlying this remains unknown. In addition, the concentrations of astaxanthin and adonixanthin detected in the brain were approximately 30 and 10 nM, respectively. These concentrations correspond to one-third and one-tenth of the minimum concentration (0.1 μM) used in the cell proliferation test, as shown in Figure 2A,B. In glioblastoma pathology, invasive glioblastoma cells degrade the basement membrane around blood vessels and cause disruption of the blood–brain barrier. As a result, the transferability to the brain of immune cells and chemotherapeutic drugs is increased [39,40]. In a study using a glioma rat model, it was reported that translocation of a magnetic resonance imaging (MRI) contrast agent increased about five times in tumour tissues compared with its translocation in healthy tissues [41]. Therefore, it is inferred that astaxanthin and adonixanthin administered orally accumulate in glioblastoma tissues at higher concentrations compared with their accumulation in healthy tissues.
Next, using an in vivo glioblastoma mouse model, we examined whether the oral administration of astaxanthin and adonixanthin exhibited an antitumour effect on glioblastoma. Both astaxanthin and adonixanthin significantly suppressed tumour growth in this in vivo glioblastoma model (Figure 6). These results showed that astaxanthin and adonixanthin transferred to the brain by oral administration exert an antitumour effect on glioblastoma. Although adonixanthin tended to have a greater effect than astaxanthin in this in vitro study (Figure 2, Figure 3, Figure 4 and Figure 5), astaxanthin and adonixanthin showed a comparable antitumour effect in the in vivo glioblastoma model. These results may reflect differences both in transferability to the brain and the ratio of isoforms of astaxanthin or adonixanthin.
In conclusion, these findings suggest that the oral administration of astaxanthin and adonixanthin, respectively, could be potentially useful treatments for glioblastoma.

4. Materials and Methods

4.1. Reagents

Both astaxanthin and adonixanthin obtained from Paracoccsu carotinifaciens were provided by ENEOS Corporation (Tokyo, Japan). Adonixanthin is an intermediate compound between zeaxanthin and astaxanthin [42,43]. These compounds were dissolved by dimethyl sulfoxide, DMSO (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), on in vitro and diffused by olive oil (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) on in vivo. In the in vitro study, the final concentration of DMSO in all the groups was 0.1%.

4.2. Cell Line and Culture Condition

The human glioblastoma cell line U251MG was purchased from European Collection of Authenticated Cell Cultures (ECACC; London, the United Kingdom). The murine glioblastoma cell line GL261 was kindly provided by Dr. Saio, Graduate School of Health Sciences, Gunma University. The human glioblastoma cell line U87MG was obtained from American Type Culture Collection (ATCC). These cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with low glucose (Nacalai Tesque, Tokyo, Japan) supplemented with 10% foetal bovine serum (FBS; Valeant, Costa Mesa, CA, USA), 100 units/mL penicillin, and 100 mg/mL streptomycin at 37 °C in 5% CO₂. Cells were passaged by trypsinization and used within 10 passages.

4.3. Cell Viability

U251MG, GL261, or U87MG cells were seeded onto 96-well plates at a density of 2 × 103 cells/well with DMEM supplemented with 10% FBS and then incubated for 24 h, after which the culture medium was changed to DMEM containing 10% FBS. Then, astaxanthin, adonixanthin or temozolomide (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) were added to the culture. Cell proliferation was determined using the CCK-8 assay according to the manufacturer’s instructions (Dojindo, Kumamoto, Japan). After each incubation, 10 μL of CCK-8 solution were added to each well. Plates were incubated for 3 h for 37 °C, and the absorbance was read at 450 nm with a reference wavelength of 630 nm using a Varioscan Flash 2.4 microplate reader (Thermo Fisher Scientific, Waltham, MA, USA).

4.4. BrdU (Bromodeoxyuridine) Cell Proliferation Assay

GL261 cells were seeded onto 96-well plates at a density of 2 × 103 cells/well with DMEM supplemented with 10% FBS and then incubated for 24 h, after which the culture medium was changed to DMEM containing 10% FBS. Then, astaxanthin, adonixanthin, or temozolomide (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) were added to the culture. After 72 h of culture, the culture medium was changed to DMEM containing 10% FBS and treated with BrdU at 10 µM for 3 h. After that, immunocytochemistry was performed according to the protocol of anti-BrdU antibody (abcam, ab6326).

4.5. Cell Migration Assay

The cell migration assay was conducted as previously described [44].
GL261 cells and U251 cells (2.0 × 104 cells per well) were plated in a 12-well plate (BD Biosciences, Tokyo, Japan) with culture medium supplemented with 10% FBS. After 24 h of incubation, the medium was changed to DMEM containing 1% FBS. After 6 h, wounds were scratched by a P1000 pipette tip and washed with phosphate-buffered saline (PBS) to eliminate cell debris. Then, fresh medium was added with 10 µM astaxanthin or adonixanthin. Pictures were taken at 48 h and these scratched areas were measured using an All-in-One Fluorescence Microscope (BZ-X710; Keyence, Osaka, Japan). The cell migration rate was measured the area of the wound before migration (S0) and after migration (S1) and calculated S1/(S0−S1) × 100. The control group was then standardized to be 100%. Wound widths at 0 h were created within 1 to 1.5 mm and data were excluded if they were not suitable for that width.

4.6. Immunoblotting

GL261 cell was seeded at 2.5 × 104 cells per well in 24-well plates with culture medium supplemented with 10% FBS. After 24 h of incubation, the medium was changed to DMEM containing 10% FBS and 0.1%DMSO PBS, 300 μM temozolomide, 10 µM astaxanthin, or 10 µM adonixanthin was added for 6 and 48 h. Cells were lysed in a special buffer (RIPA buffer R0278; Sigma-Aldrich, St. Louis, MO, USA) with a protease inhibitor cocktail (Sigma-Aldrich), phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich), and sample buffer (Wako, Osaka, Japan). The protein concentration was determined by comparison with a known concentration of bovine serum albumin using the BCA Protein Assay Kit (Thermo Fisher Scientific). The amount of total protein was 2 µg. Equal amounts of protein in sample buffer containing 10% 2-mercaptoethanol were subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) in 5–20% gradient gels (SuperSep Ace; Wako), and the separated proteins were transferred to polyvinylidene difluoride membrane (Immobilon-P; Merck Millipore Corporation, Bedford, MA, USA). After blocking for 30 min with Blocking One-P (Nacalai Tesque), we incubated the membranes with primary antibodies overnight at 4 °C. The primary antibodies were a rabbit anti-phospho-p44/42 MAPK; ERK1/2 (T202/Y204) 197G2 (4377S, Cell signalling, diluted 1:1000), a rabbit anti-p44/42 MAPK; ERK1/2 (9102S, Cell signalling, diluted 1:1000), a rabbit anti-phospho-Akt (S473) 193H12 (4058S, Cell signalling, diluted 1:1000), a rabbit anti-Akt (9272S, Cell signalling, diluted 1:1000), a rabbit anti-phospho-p38 MAPK (T180/Y182) (9211S, Cell signalling, diluted 1:1000), a rabbit anti-p38 MAPK (9212S, Cell signalling, diluted 1:1000), a rabbit anti-mmp-2 (AB19167, Chemicon®, diluted 1:1000), a rabbit anti-mmp-9 (AB19016, Chemicon®, diluted 1:1000), a rabbit anti-fibronectin (ab2413, abcam, diluted 1:1000), a rabbit anti-cyclin D1 (2978, Cell signalling, diluted 1:1000), a mouse anti-p27 (sc-1641, Santa Cluz, diluted 1:500), a rabbit anti-Nox4 (NB110-5849SS, Novus, diluted 1:500), a mouse anti-Bcl-2 (sc-7382, Santa Cluz, diluted 1:500), and a mouse anti-β-actin antibody (#A2228, Sigma-Aldrich, diluted 1:1000).
After that, the membrane was incubated with the following secondary antibodies: a goat anti-rabbit IgG, or a goat anti-mouse IgG antibody (Thermo Fisher Scientific, diluted 1:1000). The band intensity was measured using an Immuno Star LD (Wako). Band intensity was measured using an LAS-4000 UV mini Luminescent Image Analyzer (Fujifilm, Tokyo Japan) and Multi Gauge Version 3.0 (Fujifilm). The phosphorylation of ERK1/2, Akt, and p38 MAPK was measured by normalizing against total ERK1/2, total Akt, and total p38 MAPK. Equal loading was confirmed using β-actin as controls for phosphoprotein signals.

4.7. Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction Analysis (qRT-PCR)

To evaluate the effect of astaxanthin and adonixanthin on the expression of Fibronectin mRNA expression, we performed quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) analysis. GL261 cell was seeded at 2.5 × 104 cells well in 24-well plates with culture medium supplemented with 10% FBS. After 24 h of incubation, the medium was changed to DMEM containing 10% FBS and 0.1% DMSO PBS, 300 μM temozolomide, 10 µM astaxanthin, or 10 µM adonixanthin was added for 48 h. After 48 h of treatment, RNA was isolated from GL261 cells using Nucleo Spin RNA II (Takara, Shiga, Japan). RNA concentrations were determined using NanoVue Plus (GE Healthcare Japan, Tokyo, Japan). Single-strand cDNAs were synthesized from the isolated RNAs via reverse transcription with a PrimeScript RT Reagent Kit (Perfect Real Time; Takara). Quantitative real-time RT-PCR was performed using TB Green Premix Ex Taq II (Tli RNaseH Plus; Takara) and a TP800 Thermal Cycler Dice Real Time System (Takara). All procedures were carried out in accordance with the manufacturer’s instructions. The PCR primer sequences for Fibronectin were as follows: 5′-CGA GGT GAC AGA GAC CAC AA-3′ (forward) and 5′-CTG GAG TCA AGC CAG ACA CA -3′ (reverse). β-actin (internal control) was as follows: 5′-CAT CCG TAA AGA CCT CTA TGC CAA C-3′ (forward) and 5′-ATG GAG CCA CCG ATC CAC A-3′ (reverse). The cycling conditions were in accordance with the manufacturer’s protocol. The results are expressed as relative gene expression levels normalized to that of β-actin.

4.8. Cell Death Assay

GL261 cells were seeded onto 96-well plates at a density of 2 × 103 cells/well with DMEM supplemented with 10% FBS and then incubated for 24 h, after which the culture medium was changed to DMEM containing 10% FBS. Then, astaxanthin, adonixanthin, or temozolomide (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) were added to the culture. Cell death was measured by Hoechst 33,342 (Invitrogen, Carlsbad, CA, USA) and propidium iodide (Invitrogen). At 96 h after treatment, the Hoechst 33,342 and propidium iodide were added to the medium to final concentrations of 8.1 and 1.5 µM, respectively, for 15 min. Images of stained cells were captured with a Lionheart™ FX Automated Microscope (BioTek, Tokyo, Japan). The percentage of propidium iodide-positive cells was determined by distinguishing Hoechst 33,342 and propidium iodide fluorescence.

4.9. Reactive Oxygen Species Assay

Intracellular radical activation within GL261 cells was measured with 5-(and-6)-chloromethyl—2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA; Thermo Fisher Scientific, MA, USA). Six hours after treatment of temozolomide, astaxanthin, or adonixanthin, CM-H2DCFDA was added to the culture medium and incubated at 37 °C for 1 h under shading in GL261. Fluorescence was measured using a Varioscan Flash 2.4 microplate reader (Thermo Fisher Scientific, MA, USA) at 485 (excitation)-535 nm (emission). Measurements were performed 0, 30, and 60 min after the addition of CM-H2DCFDA.

4.10. Animals

All experimental design and procedures were approved by the murine experiment committees of Gifu Pharmacological University and were in compliance with ARRIVE (Animal Research: Reporting in Vivo Experiments) guidelines. These experiments were approved by the animal experiment committees of Gifu Pharmaceutical University, Japan (Ethic nos. 2018-099, 2019-065). For all experiments, male C57BL/6J mice (8 weeks old; body weight 22~27 g) and male ICR mice (6 weeks old; body weight 25~28 g) purchased from Japan SLC, Inc. (Hamamatsu, Shizuoka, Japan) were used. Animals were housed at 24 ± 2 °C under a 12-h light-dark cycle. Food and water were available to all animals ad libitum. All experimental procedures and outcome assessments were performed in a blinded manner.

4.11. Murine orthotopic Glioblastoma Model

Murine glioblastoma cell (GL261) transplantation was performed as previously described [39]. Briefly, mice received an intracranial injection of 1 × 105 cells in 2 µL of PBS using a Hamilton microliter syringe at the following coordinates: 1 mm anterior, 2 mm lateral (left of middle) to bregma, at a depth of 3 mm from the dural surface. This protocol was completed using a stereotactic frame.

4.12. In Vivo Drug Treatment

In the experiment of the murine orthotopic glioblastoma model, oral administration of each astaxanthin (10 and 30 mg/kg) and adonixanthin (10 and 30 mg/kg) was initiated 3 days after intracranial injection of GL261 cells and was continued for 10 days. In the experiment of the brain tissue absorption with oral astaxanthin or adonixanthin, after one week of adaptation, ICR mice were randomly divided into the following three groups: control group, astaxanthin group (50 mg/kg), and adonixanthin group (50 mg/kg). Mice were orally administered each reagent suspended in olive oil (5 mL/kg) by the daily single dose for 10 days. The control group was treated by olive oil alone (5 mL/kg).
Since 50 mg/kg is known to be a dose of astaxanthin that does not show adverse effects even with long-term administration, this dose of astaxanthin and adonixanthin was used in the distribution experiment of this study. Moreover, it was reported that the oral administration of astaxanthin at 25 mg/kg inhibited hippocampal inflammation in diabetic mice [45]. Thus, we set up a dose similar to that in the present study.

4.13. Mouse Brain Analysis on In Vivo Glioblastoma Model

Mice were euthanized and transcranial perfused with cold saline for 2 min at room temperature. After that, the perfusate was changed to 0.1 M phosphate buffer (PB; pH 7.4) containing 4% paraformaldehyde (PFA, Wako Pure Chemicals, Osaka, Japan) for 3 min. Brains were fixed in 4% paraformaldehyde, embedded in paraffin (Leica Biosystems, Wetzlar, Germany), cut into 5-µm sections, and processed for haematoxylin-eosin (HE) staining. Pictures were taken using an All-in-One Fluorescence Microscope (BZ-X710; Keyence, Osaka, Japan). We assessed the maximum cross-sectional area of the tumour and tumour volume as described previously [46].

4.14. Collecting Blood and Tissues

In mice, blood samples were collected under anaesthesia by using sodium pentobarbital (50 mg/kg, 10 mL/kg, i.p). To separate serum and from blood, we centrifuged at 1700 g for 10 min. After mice were euthanized by exsanguination under deep anaesthesia, tissues, such as brain, were picked. Furthermore, the cerebral cortex, cerebellum, striatum, and hippocampus were separated from the whole brain.
All samples, including serum and tissues, were stored at −80 °C until the analysis of astaxanthin and adonixanthin was performed.

4.15. Analysis of Astaxanthin and Adonixanthin

Carotenoid fraction was collected from blood and some tissues by silica gel HPLC using a Cosmosil 5SL-II column with acetone:hexane (2:8, v/v) for the mobile phase at a flow rate of 1.0 mL/min as described above. This fraction was evaporated to dryness, dissolved in isopropanol: hexane (4:96, v/v), and subjected to chiral HPLC. Identification of each carotenoid was performed by authentic carotenoids obtained from Paracoccus (ENEOS Corporation, Tokyo, Japan) by our routine methods [47] and the content of each carotenoid was calculated from peak areas by comparison with the authentic samples.

4.16. Statistical Analysis

All data are presented as mean ± standard error of the mean (SEM). We performed the experiments assuming normality and selected an appropriate statistical analysis method depending on the presence or absence of equal variance. Specifically, student’s t-test or Welch’s test was used in the case of equal or non-equal variance under Bonferroni correction in Figure 2D, Figure 3, Figure 4, Figure 5B, and Figures S3–S5. We used a one-way analyses of variance (ANOVA) followed by Tukey’s test or Games-Howell’s test for multiple comparisons in Figure 2A, Figure 2B, Figure 5A, Figure 6, Figures S1 and S2; and the Mann–Whitney U-test for two-group comparisons in Table 2 and Supplementary Material Table S1. These statistics were performed by SPSS Statistics (IBM, Armonk, NY, USA) software. p < 0.05 was considered statistical significance.

Supplementary Materials

The following are available online at https://www.mdpi.com/1660-3397/18/9/474/s1, Figure S1, Supplemental Figure 1. Cell viability of mouse and human glioblastoma cell line with astaxanthin and adonixanthin., Figure S2, Cell viability of human glioblastoma cell line U87MG with astaxanthin and adonixanthin, Figure S3, Expression of Fibronectin mRNA after 48 h treatment of astaxanthin and adonixanthin in mouse glioblastoma cell line. Figure S4, The effect of astaxanthin and adonixanthin for cell death. Figure S5, The effects of astaxanthin and adonixanthin on body weight. Table S1: Astaxanthin or adonixanthin levels in the mouse tissues without brain.

Author Contributions

Conceptualization, S.T., S.N., H.H. and M.S. (Masamitsu Shimazawa); Data curation, S.T., S.N. and M.S. (Masamitsu Shimazawa); Formal analysis, S.T.; Funding acquisition, H.H.; Investigation, S.T., T.M., T.Y. (Tetsuya Yamada), T.I., T.O. and T.Y. (Tomohiro Yako); Methodology, S.T., S.N., H.H. and M.S. (Masamitsu Shimazawa); Project administration, S.N. and H.H.; Resources, M.H., K.E. and M.S. (Masanao Saio); Software, S.T.; Supervision, S.N. and H.H.; Validation, S.N. and M.S. (Masamitsu Shimazawa); Visualization, S.T., S.N., H.H. and M.S. (Masamitsu Shimazawa); Writing—original draft, S.T.; Writing—review & editing, S.N., M.S., H.H. and M.S. (Masamitsu Shimazawa). All authors have read and agreed to the published version of the manuscript.

Funding

Dr. Hara had grants from ENEOS Corporation (Tokyo, Japan). The other authors declare no competing financial interest.

Conflicts of Interest

This study was funded by ENEOS Corporation (Tokyo, Japan). M.K. and K.E are employees of ENEOS Corporation.

References

  1. Friedman, H.S.; Kerby, T.; Calvert, H. Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 2000, 6, 2585–2597. [Google Scholar]
  2. Stupp, R.; Taillibert, S.; Kanner, A.A.; Kesari, S.; Steinberg, D.M.; Toms, S.A.; Taylor, L.P.; Lieberman, F.; Silvani, A.; Fink, K.L.; et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA 2015, 314, 2535–2543. [Google Scholar] [CrossRef] [PubMed]
  3. Stupp, R.; Mason, W.P.; Van Den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [Google Scholar] [CrossRef] [PubMed]
  4. Ostrom, Q.T.; Gittleman, H.; Liao, P.; Rouse, C.; Chen, Y.; Dowling, J.; Wolinsky, Y.; Kruchko, C.; Barnholtz-Sloan, J. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro. Oncol. 2014, 16, iv1–iv63. [Google Scholar] [CrossRef] [PubMed]
  5. Lacroix, M.; Abi-Said, D.; Fourney, D.R.; Gokaslan, Z.L.; Shi, W.; DeMonte, F.; Lang, F.F.; McCutcheon, I.E.; Hassenbusch, S.J.; Holland, E.; et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J. Neurosurg. 2001, 95, 190–198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Warren, K.E. Beyond the blood: Brain barrier: The importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors, including diffuse intrinsic pontine glioma. Front. Oncol. 2018, 8, 239. [Google Scholar] [CrossRef] [Green Version]
  7. Zhao, M.; Zhao, M.; Fu, C.; Yu, Y.; Fu, A. Targeted therapy of intracranial glioma model mice with curcumin nanoliposomes. Int. J. Nanomed. 2018, 13, 1601–1610. [Google Scholar] [CrossRef] [Green Version]
  8. Clark, P.A.; Bhattacharya, S.; Elmayan, A.; Darjatmoko, S.R.; Thuro, B.A.; Yan, M.B.; Van Ginkel, P.R.; Polans, A.S.; Kuo, J.S. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. J. Neurosurg. 2017, 126, 1448–1460. [Google Scholar] [CrossRef] [Green Version]
  9. Maoka, T.; Yasui, H.; Ohmori, A.; Tokuda, H.; Suzuki, N.; Osawa, A.; Shindo, K.; Ishibashi, T. Anti-oxidative, anti-tumor-promoting, and anti-carcinogenic activities of adonirubin and adonixanthin. J. Oleo Sci. 2013, 62, 181–186. [Google Scholar] [CrossRef] [Green Version]
  10. Miki, W.; Yamaguchi, K.; Konosu, S. Comparison of carotenoids in the ovaries of marine fish and shellfish. Comp. Biochem. Physiol. Part B Biochem. 1982, 71, 7–11. [Google Scholar] [CrossRef]
  11. Nakajima, Y.; Inokuchi, Y.; Shimazawa, M.; Otsubo, K.; Ishibashi, T.; Hara, H. Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. J. Pharm. Pharmacol. 2008, 60, 1365–1374. [Google Scholar] [CrossRef] [PubMed]
  12. Nishioka, Y.; Oyagi, A.; Tsuruma, K.; Shimazawa, M.; Ishibashi, T.; Hara, H. The antianxiety-like effect of astaxanthin extracted from Paracoccus carotinifaciens. BioFactors 2011, 37, 25–30. [Google Scholar] [CrossRef] [PubMed]
  13. Murata, K.; Oyagi, A.; Takahira, D.; Tsuruma, K.; Shimazawa, M.; Ishibashi, T.; Hara, H. Protective Effects of Astaxanthin from Paracoccus carotinifaciens on Murine Gastric Ulcer Models. Phyther. Res. 2012, 26, 1126–1132. [Google Scholar] [CrossRef] [PubMed]
  14. Otsuka, T.; Shimazawa, M.; Nakanishi, T.; Ohno, Y.; Inoue, Y.; Tsuruma, K.; Ishibashi, T.; Hara, H. The protective effects of a dietary carotenoid, astaxanthin, against light-induced retinal damage. J. Pharmacol. Sci. 2013, 123, 209–218. [Google Scholar] [CrossRef] [Green Version]
  15. Otsuka, T.; Shimazawa, M.; Inoue, Y.; Nakano, Y.; Ojino, K.; Izawa, H.; Tsuruma, K.; Ishibashi, T.; Hara, H. Astaxanthin Protects Against Retinal Damage: Evidence from In Vivo and In Vitro Retinal Ischemia and Reperfusion Models. Curr. Eye Res. 2016, 41, 1465–1472. [Google Scholar] [CrossRef]
  16. Inoue, Y.; Shimazawa, M.; Nagano, R.; Kuse, Y.; Takahashi, K.; Tsuruma, K.; Hayashi, M.; Ishibashi, T.; Maoka, T.; Hara, H. Astaxanthin analogs, adonixanthin and lycopene, activate Nrf2 to prevent light-induced photoreceptor degeneration. J. Pharmacol. Sci. 2017, 134, 147–157. [Google Scholar] [CrossRef]
  17. Pan, L.; Zhou, Y.; Li, X.F.; Wan, Q.J.; Yu, L.H. Preventive treatment of astaxanthin provides neuroprotection through suppression of reactive oxygen species and activation of antioxidant defense pathway after stroke in rats. Brain Res. Bull. 2017, 130, 211–220. [Google Scholar] [CrossRef]
  18. Iwata, S.; Imai, T.; Shimazawa, M.; Ishibashi, T.; Hayashi, M. Protective e ff ects of the astaxanthin derivative, adonixanthin, on brain hemorrhagic injury. Brain Res. 2018, 1698, 130–138. [Google Scholar] [CrossRef]
  19. Kavitha, K.; Kowshik, J.; Kishore, T.K.K.; Baba, A.B.; Nagini, S. Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim. Biophys. Acta Gen. Subj. 2013, 1830, 4433–4444. [Google Scholar] [CrossRef]
  20. Tanaka, T.; Morishita, Y.; Suzui, M.; Kojima, T.; Okumura, A.; Mori, H. Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin. Carcinogenesis 1994, 15, 15–19. [Google Scholar] [CrossRef]
  21. Nagendraprabhu, P.; Sudhandiran, G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Investig. N. Drugs 2011, 29, 207–224. [Google Scholar] [CrossRef] [PubMed]
  22. Zhang, X.; Zhao, W.; Hu, L.; Zhao, L.; Huang, J. Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPAR c) in K562 cancer cells. Arch. Biochem. Biophys. 2011, 512, 96–106. [Google Scholar] [CrossRef] [PubMed]
  23. Ong, X.S.; Hang, J.Z.; Ang, M.W.; Iu, W.L.; Xin-bin, G.U. Astaxanthin Induces Mitochondria-Mediated Apoptosis in Rat Hepatocellular Carcinoma CBRH-7919 Cells. Biol. Pharm. Bull. 2011, 34, 839–844. [Google Scholar]
  24. Zhang, L.; Wang, H. Multiple mechanisms of anti-cancer effects exerted by astaxanthin. Mar. Drugs 2015, 13, 4310–4330. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Mccubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, W.T.; Chang, F.; Lehmann, B.; Terrian, D.M.; Milella, M.; Stivala, F.; et al. Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2009, 1773, 1263–1284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Wee, P.; Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers 2017, 9, 52. [Google Scholar]
  27. Wu, W.-S.; Wu, J.-R.; Hu, C.-T. Signal cross talks for sustained MAPK activation and cell migration: The potential role of reactive oxygen species. Cancer Metastasis Rev. 2008, 27, 303–314. [Google Scholar] [CrossRef]
  28. Jhou, B.; Song, T.; Lee, I.; Hu, M.; Yang, N. Lycopene Inhibits Human liver adenocarcinoma SK-Hep-1 Cells Metastasis by Down Regulation of NADPH Oxidase 4 Protein Expression. J. Agric. Food Chem. 2017, 65, 6893–6903. [Google Scholar] [CrossRef]
  29. Hayashi, M.; Ishibashi, T.; Maoka, T. Effect of astaxanthin rich extract derived from Paracoccus carotinifaciens on cognitive function in middle aged and older individuals. J. Clin. Biochem. Nutr. 2018, 62, 195–205. [Google Scholar] [CrossRef] [Green Version]
  30. Zhang, J.; Cao, M.; Yang, W.; Sun, F.; Xu, C.; Yin, L.; Pu, Y. Inhibition of Glucose-6-Phosphate Dehydrogenase Could Enhance 1, 4-Benzoquinone-Induced Oxidative Damage in K562 Cells. Oxid. Med. Cell. Longev. 2016, 2016, 3912515. [Google Scholar] [CrossRef] [Green Version]
  31. Zhu, W.; Xue, Y.; Liang, C.; Zhang, R.; Zhang, Z.; Li, H.; Su, D.; Liang, X.; Zhang, Y.; Huang, Q.; et al. S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2016, 37, 12241–12250. [Google Scholar] [CrossRef] [PubMed]
  32. Peng, X.; Liu, Y.; Zhu, S.; Peng, X.; Li, H.; Jiao, W.; Lin, P.; Zhang, Z.; Qiu, Y.; Jin, M.; et al. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2019, 145, 2921–2936. [Google Scholar] [CrossRef]
  33. Bi, T.; Zhu, A.; Yang, X.; Qiao, H.; Tang, J.; Liu, Y.; Lv, R. Metformin synergistically enhances antitumor activity of cisplatin in gallbladder cancer via the PI3K/AKT/ERK pathway. Cytotechnology 2018, 70, 439–448. [Google Scholar] [CrossRef] [PubMed]
  34. Meco, D.; Servidei, T.; Lamorte, G.; Binda, E.; Arena, V.; Riccardi, R. Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. Neuro. Oncol. 2014, 16, 1067–1077. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Aggarwal, V.; Tuli, H.S.; Varol, A.; Thakral, F.; Yerer, M.B.; Sak, K.; Varol, M.; Jain, A.; Khan, M.A.; Sethi, G. Role of reactive oxygen species in cancer progression: Molecular mechanisms and recent advancements. Biomolecules 2019, 9, 735. [Google Scholar] [CrossRef] [Green Version]
  36. Shono, T.; Yokoyama, N.; Uesaka, T.; Kuroda, J.; Takeya, R.; Yamasaki, T.; Amano, T.; Mizoguchi, M.; Suzuki, S.O.; Niiro, H.; et al. Enhanced expression of NADPH oxidase Nox4 in human gliomas and its roles in cell proliferation and survival. Int. J. Cancer 2008, 123, 787–792. [Google Scholar] [CrossRef]
  37. Zhou, Q.; Xu, J.; Yang, L.; Gu, C.; Xue, C. Thermal stability and oral absorbability of astaxanthin esters from Haematococcus pluvialis in Balb/c mice. J. Sci. Food Agric. 2019, 99, 3662–3671. [Google Scholar] [CrossRef]
  38. Yang, C.; Zhang, H.; Liu, R.; Zhu, H.; Zhang, L.; Tsao, R. Bioaccessibility, Cellular Uptake, and Transport of Astaxanthin Isomers and their Antioxidative Effects in Human Intestinal Epithelial Caco-2 Cells. J. Agric. Food Chem. 2017, 65, 10223–10232. [Google Scholar] [CrossRef]
  39. Cuddapah, V.A.; Robel, S.; Watkins, S.; Sontheimer, H. A neurocentric perspective on glioma invasion. Nat. Rev. Neurosci. 2014, 15, 455–465. [Google Scholar] [CrossRef] [Green Version]
  40. Gao, X.; Yue, Q.; Liu, Y.; Fan, D.; Fan, K.; Li, S.; Qian, J.; Han, L.; Fang, F.; Xu, F.; et al. Image-guided chemotherapy with specifically tuned blood brain barrier permeability in glioma margins. Theranostics 2018, 8, 3126–3137. [Google Scholar] [CrossRef]
  41. Blanchette, M.; Tremblay, L.; Lepage, M.; Fortin, D. Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption. J. Cereb. Blood Flow Metab. 2014, 34, 820–826. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Breitenbach, J. Expression in Escherichia coZi and properties of the carotene ketolase from Haematococcus pluvialis. FEMS Microbiol. Lett. 1996, 140, 241–246. [Google Scholar] [CrossRef] [PubMed]
  43. Rhodes, A.C.E. Dietary effects on carotenoid composition in the marine harpacticoid copepod Nitokra lacustris. J. Plankton Res. 2007, 29, i73–i83. [Google Scholar] [CrossRef]
  44. Tsuji, S.; Ohno, Y.; Nakamura, S.; Yamada, T.; Noda, Y. Temozolomide has anti-tumor e ff ects through the phosphorylation of cPLA 2 on glioblastoma cells. Brain Res. 2019, 1723, 146396. [Google Scholar] [CrossRef]
  45. Zhou, X.-Y.; Zhang, F.; Hu, X.-T.; Chen, J.; Tang, R.-X.; Zheng, K.-Y.; Song, Y.-J. Depression can be prevented by astaxanthin through inhibition of hippocampal inflammation in diabetic mice. Brain Res. 2017, 1657, 262–268. [Google Scholar] [CrossRef]
  46. Duan, J.; Gao, Y.; Zhang, X.; Wang, X.; Wang, B.; Meng, X. International Immunopharmacology CD30 ligand de fi ciency accelerates glioma progression by promoting the formation of tumor immune microenvironment. Int. Immunopharmacol. 2019, 71, 350–360. [Google Scholar] [CrossRef]
  47. Maoka, T. Structural studies of carotenoids in plants, animals, and food products. In Carotenoids; Wiley: Hoboken, NJ, USA, 2016; pp. 103–129. [Google Scholar]
Marinedrugs 18 00474 g001 550
Figure 1. The chemical structure of astaxanthin and adonixanthin. (A) Astaxanthin (B) Adonixanthin.
Figure 1. The chemical structure of astaxanthin and adonixanthin. (A) Astaxanthin (B) Adonixanthin.
Marinedrugs 18 00474 g001
Marinedrugs 18 00474 g002 550
Figure 2. Cell viability of the mouse and human glioblastoma cell line with astaxanthin and adonixanthin. (A, B) These graphs show the cell viability of GL261 (mouse glioblastoma cell line) and U251MG (human glioblastoma cell line) treated for 96 h with temozolomide, astaxanthin, or adonixanthin. Data are shown as mean ± SEM (n = 6). ** p < 0.01 vs. control group (Tukey’s test). (C) These images show the representative photographs of the BrdU assay 96 h after treatment of temozolomide, astaxanthin, or adonixanthin in GL261. (D) This graph shows the BrdU-positive cells (%). Data are shown as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01 vs. control group (Student’s t-test). TMZ; temozolomide.
Figure 2. Cell viability of the mouse and human glioblastoma cell line with astaxanthin and adonixanthin. (A, B) These graphs show the cell viability of GL261 (mouse glioblastoma cell line) and U251MG (human glioblastoma cell line) treated for 96 h with temozolomide, astaxanthin, or adonixanthin. Data are shown as mean ± SEM (n = 6). ** p < 0.01 vs. control group (Tukey’s test). (C) These images show the representative photographs of the BrdU assay 96 h after treatment of temozolomide, astaxanthin, or adonixanthin in GL261. (D) This graph shows the BrdU-positive cells (%). Data are shown as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01 vs. control group (Student’s t-test). TMZ; temozolomide.
Marinedrugs 18 00474 g002
Marinedrugs 18 00474 g003 550
Figure 3. Wound healing assay with astaxanthin and adonixanthin in human glioblastoma cell U251MG and mouse glioblastoma cell line GL261. (A,C) These images show representative photographs of the wound healing assay 48 h after treatment of temozolomide, astaxanthin, or adonixanthin in GL261 (A) and U251MG (B). (B,D) These bar graphs show the cell migration abilities of GL261 (B) and U251MG (D). Data are shown as mean ± SEM (n = 3). * p < 0.05 vs. control group (Student’s t-test). Migration area ratio = (0 h scratch area—48 h non migration area)/0 h scratch area. (Original magnification × 20). The scale bars are 500 μm.
Figure 3. Wound healing assay with astaxanthin and adonixanthin in human glioblastoma cell U251MG and mouse glioblastoma cell line GL261. (A,C) These images show representative photographs of the wound healing assay 48 h after treatment of temozolomide, astaxanthin, or adonixanthin in GL261 (A) and U251MG (B). (B,D) These bar graphs show the cell migration abilities of GL261 (B) and U251MG (D). Data are shown as mean ± SEM (n = 3). * p < 0.05 vs. control group (Student’s t-test). Migration area ratio = (0 h scratch area—48 h non migration area)/0 h scratch area. (Original magnification × 20). The scale bars are 500 μm.
Marinedrugs 18 00474 g003
Marinedrugs 18 00474 g004a 550Marinedrugs 18 00474 g004b 550
Figure 4. Expression of some proteins related to tumour progression after treatment of astaxanthin and adonixanthin in the mouse glioblastoma cell line. (A,B) The quantitative data of the expression levels of p-ERK1/2 and p-Akt in the mouse glioblastoma cell line GL261 at 6 h after treatment of 300 µM temozolomide, 10 µM astaxanthin, or 10 µM adonixanthin. Both astaxanthin and adonixanthin reduced the expression of p-ERK1/2 and p-Akt. Data are shown as mean ± SEM (n = 5 or 6). * p < 0.05, ** p < 0.01 vs. control group (Student’s t-test). (C~H) The quantitative data of expression levels of p-p38, p38, cyclin D1, p27, MMP-2, -9, and fibronectin, in the mouse glioblastoma cell line GL261 at 48 h after treatment of 300 µM temozolomide, 10 µM astaxanthin, or 10 µM adonixanthin. Data are shown as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01 vs. control group (Student’s t-test). ASX; astaxanthin, ADX; adonixanthin, TMZ; temozolomide.
Figure 4. Expression of some proteins related to tumour progression after treatment of astaxanthin and adonixanthin in the mouse glioblastoma cell line. (A,B) The quantitative data of the expression levels of p-ERK1/2 and p-Akt in the mouse glioblastoma cell line GL261 at 6 h after treatment of 300 µM temozolomide, 10 µM astaxanthin, or 10 µM adonixanthin. Both astaxanthin and adonixanthin reduced the expression of p-ERK1/2 and p-Akt. Data are shown as mean ± SEM (n = 5 or 6). * p < 0.05, ** p < 0.01 vs. control group (Student’s t-test). (C~H) The quantitative data of expression levels of p-p38, p38, cyclin D1, p27, MMP-2, -9, and fibronectin, in the mouse glioblastoma cell line GL261 at 48 h after treatment of 300 µM temozolomide, 10 µM astaxanthin, or 10 µM adonixanthin. Data are shown as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01 vs. control group (Student’s t-test). ASX; astaxanthin, ADX; adonixanthin, TMZ; temozolomide.
Marinedrugs 18 00474 g004aMarinedrugs 18 00474 g004b
Marinedrugs 18 00474 g005a 550Marinedrugs 18 00474 g005b 550
Figure 5. The amount of ROS and expression of Nox-4 after treatment of astaxanthin and adonixanthin in the mouse glioblastoma cell line. (A) ROS production was measured by an ROS detecting probe (5-(and-6)-chloromethyl—2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester: CM-H2DCFDA). Treatment of astaxanthin and adonixanthin at 1 and 10 µM reduced the amount of ROS in GL261. Data are shown as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01 vs. control group (Tukey’s test). (B) Immunoblot analysis and quantification of Nox4 at 6h after treatment of temozolomide. Data are shown as mean ± SEM (n = 6). ** p < 0.01 vs. control group (Student’s t-test) and ## p < 0.01 vs. astaxanthin 10 µM group (Student’s t-test).
Figure 5. The amount of ROS and expression of Nox-4 after treatment of astaxanthin and adonixanthin in the mouse glioblastoma cell line. (A) ROS production was measured by an ROS detecting probe (5-(and-6)-chloromethyl—2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester: CM-H2DCFDA). Treatment of astaxanthin and adonixanthin at 1 and 10 µM reduced the amount of ROS in GL261. Data are shown as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01 vs. control group (Tukey’s test). (B) Immunoblot analysis and quantification of Nox4 at 6h after treatment of temozolomide. Data are shown as mean ± SEM (n = 6). ** p < 0.01 vs. control group (Student’s t-test) and ## p < 0.01 vs. astaxanthin 10 µM group (Student’s t-test).
Marinedrugs 18 00474 g005aMarinedrugs 18 00474 g005b
Marinedrugs 18 00474 g006 550
Figure 6. The antitumour effect of astaxanthin and adonixanthin in the murine orthotopical glioblastoma model. (A) These images were representative photographs of haematoxylin and eosin staining of the coronal section. Control, n = 11; astaxanthin 10, 30 mg/kg treated: n = 9, 8; adonixanthin 10, 30 mg/kg treated: n = 8, 10. The scale bars are 1 mm. (B,C) These bar graphs show the tumour area and volume at 2 weeks after GL261 cell injection. The oral administration of astaxanthin and adonixanthin suppressed the glioblastoma progression in an in vivo glioblastoma model. Data are shown as mean ± SEM (n = 8–11). * p < 0.05, ** p < 0.01 vs. control group (Tukey’s test).
Figure 6. The antitumour effect of astaxanthin and adonixanthin in the murine orthotopical glioblastoma model. (A) These images were representative photographs of haematoxylin and eosin staining of the coronal section. Control, n = 11; astaxanthin 10, 30 mg/kg treated: n = 9, 8; adonixanthin 10, 30 mg/kg treated: n = 8, 10. The scale bars are 1 mm. (B,C) These bar graphs show the tumour area and volume at 2 weeks after GL261 cell injection. The oral administration of astaxanthin and adonixanthin suppressed the glioblastoma progression in an in vivo glioblastoma model. Data are shown as mean ± SEM (n = 8–11). * p < 0.05, ** p < 0.01 vs. control group (Tukey’s test).
Marinedrugs 18 00474 g006
Table
Table 1. The concentrations of astaxanthin and adonixanthin in the murine serum.
Table 1. The concentrations of astaxanthin and adonixanthin in the murine serum.
AstaxanthinAdonixanthin
CompoundsPre-treatment4 h After the Final Oral AdministrationPre-treatment4 h after the Final Oral Administration
trans-AstaxanthinN.D.6.04 ± 1.16
cis-AstaxanthinN.D.13.4 ± 3.78
trans-Adonixanthin N.D.34.7 ± 3.00
cis-Adonixanthin N.D.35.02 ± 5.01
Data are shown as mean ± SEM (n = 4). ng/mL. N.D.; not detected.
Table
Table 2. The concentrations of astaxanthin and adonixanthin in the murine tissues.
Table 2. The concentrations of astaxanthin and adonixanthin in the murine tissues.
Brain TissuesAstaxanthinAdonixanthin
transcistranscis
Cerebral cortex5.22 ± 0.873.62 ± 1.563.24 ± 0.44 *N.D.
Cerebellum5.06 ± 1.852.43 ± 1.582.85 ± 1.05N.D.
Striatum11.37 ± 3.143.76 ± 2.062.90 ± 1.87N.D.
Hippocampus12.28 ± 1.07 *2.61 ± 1.333.63 ± 2.10N.D.
Data are shown as mean ± SEM (n = 4). ng/g. * p < 0.05 vs. cis-forms group (Mann–Whitney U-test). N.D.; not detected.

Share and Cite

MDPI and ACS Style

Tsuji, S.; Nakamura, S.; Maoka, T.; Yamada, T.; Imai, T.; Ohba, T.; Yako, T.; Hayashi, M.; Endo, K.; Saio, M.; et al. Antitumour Effects of Astaxanthin and Adonixanthin on Glioblastoma. Mar. Drugs 2020, 18, 474. https://doi.org/10.3390/md18090474

AMA Style

Tsuji S, Nakamura S, Maoka T, Yamada T, Imai T, Ohba T, Yako T, Hayashi M, Endo K, Saio M, et al. Antitumour Effects of Astaxanthin and Adonixanthin on Glioblastoma. Marine Drugs. 2020; 18(9):474. https://doi.org/10.3390/md18090474

Chicago/Turabian Style

Tsuji, Shohei, Shinsuke Nakamura, Takashi Maoka, Tetsuya Yamada, Takahiko Imai, Takuya Ohba, Tomohiro Yako, Masahiro Hayashi, Ken Endo, Masanao Saio, and et al. 2020. "Antitumour Effects of Astaxanthin and Adonixanthin on Glioblastoma" Marine Drugs 18, no. 9: 474. https://doi.org/10.3390/md18090474

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop